Antengene Announces First Patient Dosed in Phase I/II Trial of Eltanexor for the Treatment of…
Antengene Corporation Limited announced the dosing of the first patient in China in a Phase I/II trial (the HATCH trial) of eltanexor (ATG-016), a next-generation selective inhibitor of…
Read More...
Read More...
